The Effects of a Transgelin-2 Agonist Administered at Different Times in a Mouse Model of Airway Hyperresponsiveness
文献类型:期刊论文
作者 | Yuan, Hong-Kai2; Lu, Jin2; Wang, Xue-Ling2; Lv, Zhi-Ying2; Li, Bo1; Zhu, Weiliang1![]() |
刊名 | FRONTIERS IN PHARMACOLOGY
![]() |
出版日期 | 2022-06-16 |
卷号 | 13页码:8 |
关键词 | transgelin-2 agonist TSG12 administration time asthma airway hyperresponsiveness |
DOI | 10.3389/fphar.2022.873612 |
通讯作者 | Yang, Yong-Qing(yyq@shutcm.edu.cn) ; Yin, Lei-Miao(collegeylm@shutcm.edu.cn) |
英文摘要 | Airway hyperresponsiveness (AHR) is one of the most important features of asthma. Our previous study showed that inhaled transgelin-2 agonist, TSG12, effectively reduced pulmonary resistance in a mouse model of asthma in a dose-dependent manner. However, the optimal administration time of TSG12 to reduce AHR and the pharmacological effects are still unclear. In this study, the effects of TSG12 inhalation before and during AHR occurrence were examined. The results showed that the pulmonary resistance was reduced by 57% and the dynamic compliance was increased by 46% in the TSG12 Mch group (atomize TSG12 10 min before methacholine, p < 0.05 vs. model). The pulmonary resistance was reduced by 61% and the dynamic compliance was increased by 47% in the TSG12 + Mch group (atomize TSG12 and methacholine together, p < 0.05 vs. model). Quantitative real-time PCR showed that the gene expression levels of transgelin-2, myosin phosphatase target subunit-1, and myosin light chain were up-regulated by 6.4-, 1.9-, and 2.8-fold, respectively, in the TSG12 Mch group. The gene expression levels of transgelin-2, myosin phosphatase target subunit-1, and myosin light chain were up-regulated by 3.2-, 1.4-, and 1.9-fold, respectively, in the TSG12 + Mch group. The results suggested that TSG12 effectively reduces pulmonary resistance when TSG12 inhalation occurred both before and during AHR occurrence. Gene expression levels of transgelin-2 and myosin light chain were significantly up-regulated when TSG12 inhalation occurred before AHR occurrence. This study may provide a basis for the administration time of TSG12 for asthma treatment in the future. |
WOS关键词 | ALLERGIC-ASTHMA ; METHACHOLINE ; ADULTS ; LUNG |
资助项目 | National Natural Science Foundation of China[81922076] ; National Natural Science Foundation of China[81873373] ; National Natural Science Foundation of China[81973951] ; National Natural Science Foundation of China[81872797] |
WOS研究方向 | Pharmacology & Pharmacy |
语种 | 英语 |
WOS记录号 | WOS:000819163300001 |
出版者 | FRONTIERS MEDIA SA |
源URL | [http://119.78.100.183/handle/2S10ELR8/301738] ![]() |
专题 | 新药研究国家重点实验室 |
通讯作者 | Yang, Yong-Qing; Yin, Lei-Miao |
作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, Drug Discovery & Design Ctr, CAS Key Lab Receptor Res,State Key Lab Drug Res, Shanghai, Peoples R China 2.Shanghai Univ Tradit Chinese Med, Yueyang Hosp, Shanghai, Peoples R China |
推荐引用方式 GB/T 7714 | Yuan, Hong-Kai,Lu, Jin,Wang, Xue-Ling,et al. The Effects of a Transgelin-2 Agonist Administered at Different Times in a Mouse Model of Airway Hyperresponsiveness[J]. FRONTIERS IN PHARMACOLOGY,2022,13:8. |
APA | Yuan, Hong-Kai.,Lu, Jin.,Wang, Xue-Ling.,Lv, Zhi-Ying.,Li, Bo.,...&Yin, Lei-Miao.(2022).The Effects of a Transgelin-2 Agonist Administered at Different Times in a Mouse Model of Airway Hyperresponsiveness.FRONTIERS IN PHARMACOLOGY,13,8. |
MLA | Yuan, Hong-Kai,et al."The Effects of a Transgelin-2 Agonist Administered at Different Times in a Mouse Model of Airway Hyperresponsiveness".FRONTIERS IN PHARMACOLOGY 13(2022):8. |
入库方式: OAI收割
来源:上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。